This database contains 135 studies, archived under the term: "severity of illness index"
Click here to filter this large number of results.
Effectiveness of nonpharmacological approaches in patients with mild cognitive impairment
Tsolaki, Magda,
Kounti, Fotini,
Agogiatou, Christina,
Poptsi, Eleni,
Bakoglidou, Evangelia,
Zafeiropoulou, Myrto,
Soumbourou, Aikaterini,
Nikolaidou, Evdokia,
Batsila, Georgia,
Siambani, Aikaterini,
Nakou, Stella,
Mouzakidis, Christos,
Tsiakiri, Anna,
Zafeiropoulos, Stavros,
Karagiozi, Konstantina,
Messini, Chaido,
Diamantidou, Alexandra,
Vasiloglou, Maria
Background: Mild cognitive impairment (MCI) patients are at increased risk of developing dementia. There is a conflict if cognitive interventions can improve cognitive and functional performances in order to delay the development of dementia.; Objectives: This study aimed to examine the effectiveness of a holistic cognitive rehabilitation program on patients with MCI.; Methods: The participants, […]
Persons with mild or moderate Alzheimer’s disease learn to use urine alarms and prompts to avoid large urinary accidents
Lancioni, Giulio E.,
Singh, Nirbhay N.,
O’Reilly, Mark F.,
Sigafoos, Jeff,
Bosco, Andrea,
Zonno, Nadia,
Badagliacca, Francesco
This study assessed whether three patients with Alzheimer’s disease could learn to use urine alarms and caregivers’ prompts to eliminate large urinary accidents. As soon as the patient began to release urine, the alarm system presented auditory and vibratory signals. In relation to those signals, the caregiver would prompt/encourage the patient to stop urinating and […]
Improving decision-making for feeding options in advanced dementia: a randomized, controlled trial
Hanson, Laura C.,
Carey, Timothy S.,
Caprio, Anthony J.,
Lee, Tae Joon,
Ersek, Mary,
Garrett, Joanne,
Jackman, Anne,
Gilliam, Robin,
Wessell, Kathryn,
Mitchell, Susan L.
Objectives: To test whether a decision aid improves quality of decision-making about feeding options in advanced dementia.; Design: Cluster randomized controlled trial.; Setting: Twenty-four nursing homes in North Carolina.; Participants: Residents with advanced dementia and feeding problems and their surrogates.; Intervention: Intervention surrogates received an audio or print decision aid on feeding options in advanced […]
Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer’s disease
Farlow, Martin,
Veloso, Felix,
Moline, Margaret,
Yardley, Jane,
Brand-Schieber, Elimor,
Bibbiani, Francesco,
Zou, Heng,
Hsu, Timothy,
Satlin, Andrew
Background: Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer’s disease (AD), was developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal phase 3 study, presents a detailed analysis of the safety and tolerability of increasing […]
Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin
Alvarez, X. A.,
Cacabelos, R.,
Sampedro, C.,
Aleixandre, M.,
Linares, C.,
Granizo, E.,
Doppler, E.,
Moessler, H.
Background: cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14-20) included in a dose-finding study (ITT data set: N = 51; MMSE: 14-25). Results of the […]
Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone
Valen-Sendstad, Arnhild,
Engedal, Knut,
Stray-Pedersen, Babill,
Strobel, Carsten,
Barnett, Liv,
Meyer, Nicolay,
Nurminemi, Minna
Objective: To elucidate the effects of low-dose 17beta-estradiol and norethisterone (hormone therapy [HT]) versus placebo in women with Alzheimer Disease (AD) on cognition, depressive symptoms, and activities of daily living.; Design: A 12-month randomized, double-blind, placebo-controlled study, stratified by apolipoprotein E (ApoE) genotype (with versus without the epsilon4 allele), duration of education (< or =9 […]
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial
Wang, Tao,
Huang, Qiu,
Reiman, Eric M.,
Chen, Kewei,
Li, Xia,
Li, Guanjun,
Lin, Zhiguang,
Li, Chunbo,
Xiao, Shifu
Most experts consider that memantine has a symptomatic treatment, but clinical trials have not yet provided compelling evidence to support a disease-modifying effect. We investigate the effects of memantine on clinical ratings; fluorodeoxyglucose positron emission tomography (FDG-PET) measurements, which can monitor disease-modifying effect; and cerebrospinal fluid (CSF) assays in patients with moderate to severe probable […]